# EDGAR Filing Document

**Accession Number:** 0002022953
**File Stem:** 0001213900-25-074333
**Filing Date:** 2025-8
**Character Count:** 3779
**Document Hash:** d19c4f704e4deab5c0889835b9f76c83
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-074333.hdr.sgml**: 20250811

**ACCESSION NUMBER**: 0001213900-25-074333

**CONFORMED SUBMISSION TYPE**: 15-15D

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250811

**DATE AS OF CHANGE**: 20250811

**EFFECTIVENESS DATE**: 20250811

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** TheRas, Inc.
- **CENTRAL INDEX KEY:** 0002022953
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15-15D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 333-288222-01
- **FILM NUMBER:** 251202503

**BUSINESS ADDRESS:**
- **STREET 1:** 3160 PORTER DRIVE SUITE 250
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94304
- **BUSINESS PHONE:** 6504057021

**MAIL ADDRESS:**
- **STREET 1:** 3160 PORTER DRIVE SUITE 250
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94304

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 15-15D**

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.**

Commission File Number: 333-288222-01

**THERAS, INC.**

(Exact name of registrant as specified in its charter)

**256 E. Grand Avenue, Suite 104**

**South San Francisco, CA 94080**

**(650) 405-4770**<br> (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

**None**

(Title of each class of securities covered by this Form)

**None**

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

---

| | |
|:---|:---|
| Rule 12g-4(a)(1) | ☐ |
| Rule 12g-4(a)(2) | ☐ |
| Rule 12h-3(b)(1)(i) | ☒ |
| Rule 12h-3(b)(1)(ii) | ☐ |
| Rule 15d-6 | ☐ |
| Rule 15d-22(b) | ☐ |

---

Approximate number of holders of record as of the certification or notice date: 1\*

**\*** Effective as of August 11, 2025, TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics), a Delaware corporation ("BBOT"), consummated the previously announced business combination (and any other transactions contemplated thereby, the "Business Combination") with Helix Acquisition Corp. II, a Cayman Islands exempted company ("PubCo") and Helix II Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Helix ("Merger Sub"). As part of the Business Combination, (1) PubCo de-registered in the Cayman Islands and transferred by way of continuation out of the Cayman Islands and into the State of Delaware so as to migrate and domesticate as a Delaware corporation, and (2) Merger Sub merged with and into BBOT (the "Merger") with BBOT surviving the Merger as a wholly-owned subsidiary of PubCo. In connection with the consummation of the Business Combination, PubCo was renamed BridgeBio Oncology Therapeutics, Inc. This Form 15 relates solely to the reporting obligations of BBOT under the Securities Exchange Act of 1934, as amended, and does not affect the reporting obligations of PubCo under the Exchange Act.

Pursuant to the requirements of the Securities Exchange Act of 1934, TheRas, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

---

| | | |
|:---|:---|:---|
| Date: August 11, 2025 | **THERAS, INC.** | **THERAS, INC.** |
|  | By: | */s/ Eli Wallace* |
|  | Name: | Eli Wallace |
|  | Title: | Chief Executive Officer |

---